1. 21LBA Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210). (September 2015) Authors: Rosenberg, J.; Petrylak, D.; Abidoye, O.; Van der Heijden, M.S.; Hofman-Censits, J.; Necchi, A.; O'Donnell, P.H.; Balmanoukian, A.; Loriot, Y.; Retz, M.; Perez-Gracia, J.L.; Dawson, N.A.; Balar, A.; Galsky, M.D.; Fleming, M.T.; Powles, T.; Cui, N.; Mariathasan, S.; Fine, G.D.; Dreicer, R. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S720 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2637 Baseline circulating tumor cells (CTC) and serum heat shock protein 27 (Hsp27) levels are increased in advanced bladder cancer (BC) patients with poor prognostic factors: Results from the randomized phase 2 Borealis-1™ trial of first-line gemcitabine/cisplatin plus apatorsen or placebo. (September 2015) Authors: Petrylak, D.; Eigl, B.; Senkus, E.; Loriot, Y.; Twardowski, P.; Castellano, D.; Blais, N.; Sridhar, S.; Sternberg, C.; Retz, M.; Blumenstein, B.; Jacobs, C.; Stewart, P.; Bellmunt, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S525 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗